Stockscreener 앱 받기
1.67
2.34%
-0.04
Engene Therapeutics Inc 주식(ENGN)의 최신 뉴스
Form 4 enGene Therapeutics Inc. For: 25 September By Investing.com - Investing.com Canada
Form 4 enGene Therapeutics Inc. For: 25 September - Investing.com India
Form 4 enGene Therapeutics Inc. For: 25 September By Investing.com - Investing.com UK
At $1.97 a share, enGene Therapeutics (ENGN) interim medical chief bought 5,102 shares. - Stock Titan
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market - Seeking Alpha
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
EnGene Therapeutics Posts $32.501M Net Loss and $0.47 EPS for Q3 2026 (NASDAQ: ENGN) - kalkinemedia.com
enGene Therapeutics Inc. reports results for the quarter ended July 31Earnings Summary - TradingView
Engene Holdings stock rating maintained at Market Perform by Citizens - Investing.com Nigeria
Engene Holdings stock rating maintained at Market Perform by Citizens - Investing.com Canada
enGene at Wells Fargo conference: bladder cancer push gains focus By Investing.com - Investing.com Canada
ENGN: Detalimogene voraplasmid nears pivotal data and FDA filing, targeting broad NMIBC adoption - TradingView
enGene at Wells Fargo conference: bladder cancer push gains focus By Investing.com - Investing.com India
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update - BioSpace
enGene at Wells Fargo conference: bladder cancer push gains focus By Investing.com - Investing.com UK
enGene advances detalimogene bladder cancer therapy filing - grafa.com
enGene Reports $266.3M Cash, Reaffirms Q4 BLA Submission for detalimogene - Minichart
enGene Therapeutics Inc. 3Q FY2026: Net loss $32.5M, EPS ($0.47) — 10-Q Summary - TradingView
enGene Reports Q3 2026: $266.3M Cash, $32.5M Net Loss; BLA Filing Planned 4Q26 - TradingView
Gene-therapy firm enGene (ENGN) halves its staff as losses climb - Stock Titan
ENGN 10-Q FilingsenGene Therapeutics Inc SEC 10-Q - Stock Titan
enGene Reports $32.5 Million Third-Quarter Net Loss and $266.3 Million Cash - Quiver Quantitative
A bladder cancer treatment study reported complete responses in 54% of patients - Stock Titan
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update - Business Wire
enGene Therapeutics Inc. expected to post a loss of 43 cents a shareEarnings Preview - TradingView
EnGene to Spotlight Bladder Cancer Gene Therapy at Major Investor Conferences - TipRanks
enGene to Participate in Upcoming Investor Conferences - Yahoo Finance
enGene to Participate in Upcoming Investor Conferences - Business Wire
Deep Track Capital Exits enGene Therapeutics (ENGN) Stake in Sec - GuruFocus
enGene Holdings Warrants (ENGNW) Surge 13.55% to $0.24 as Gene Therapy Speculation Heats UpVolatility Skew - careplusvn.com
enGene Holdings Warrants (ENGNW) Surge 13.55% to $0.24 as Gene Therapy Speculation Heats UpValue Stock Ideas - dars.gov.et
enGene Holdings Warrants (ENGNW) Surge 13.55% to $0.24 as Gene Therapy Speculation Heats UpZigzag Correction - dars.gov.et
enGene Therapeutics Inc. Stock 12‑Month Price Target Cut to $3.43, Implies 102% Upside - TradingView
enGene (NASDAQ:ENGN) Raised to "Sell" at Wall Street Zen - MarketBeat
Perceptive Advisors (NASDAQ: ENGN) discloses 9.99% beneficial stake with warrant cap - Stock Titan
enGene Holdings (ENGN): Venrock investor group reports 0.0% stake and no voting power - Stock Titan
Deep Track exits enGene Therapeutics (ENGN) position, reports 0% ownership - Stock Titan
Raymond Debbane (ENGN) discloses 9.3% enGene stake via Invus and Avicenna - Stock Titan
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market - MarketBeat
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market - Yahoo Finance
Blue Owl Capital Holdings (ENGN) discloses 0.76% warrant-based stake in enGene - Stock Titan
enGene Therapeutics Inc. (S0N0.F) analyst ratings, estimates and forecasts - uk.finance.yahoo.com
enGene highlights detalimogene NMIBC KOL insights and outlook - TipRanks
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder CancerSlideshow (NASDAQ:ENGN) 2026-08-11 - Seeking Alpha
enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
enGene Therapeutics Inc. (S0N0.F) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026 - Business Wire
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
enGene Therapeutics Inc. Revenue Breakdown – BOATS:ENGNW - TradingView
4.22%
자본화:
|
볼륨(24시간):